Bioverativ

GBT adds 2 Sanofi sickle cell meds in deal worth up to $353M

In exchange for the global rights to the assets, Sanofi will receive up to $353 million in an upfront fee and milestone payments.

Amirah Al Idrus Mar 16, 2021 9:55am

Sanofi nabs speedy review of sutimlimab

May 15, 2020 8:15am

Ex-Bioverativ CEO John Cox lands at Torque Therapeutics

Oct 2, 2019 7:43am